论文部分内容阅读
目的 研究尿激酶型纤溶酶原激活剂（uPA）及受体（uPAR）在髓母细胞瘤中的表达及临床意义。方法 应用免疫组化LSAB法检测50例髓母细胞瘤中uPA及uPAR的表达,结合临床随访,使用Cox回归统计分析。结果 uPA及uPAR染色定位于肿瘤细胞和血管内皮细胞。Cox回归分析显示uPA及uPAR是影响生存时间的预后因子,它们与预后存在一定的负相关关系。结论 uPA及uPAR可作为预测髓母细胞瘤患者预后的客观指标。
Objective To study the expression and clinical significance of urokinase-type plasminogen activator (uPA) and receptor (uPAR) in medulloblastoma. Methods The expression of uPA and uPAR in 50 cases of medulloblastoma was detected by immunohistochemical LSAB method. Combined with clinical follow-up, Cox regression analysis was used. Results uPA and uPAR staining localized in tumor cells and vascular endothelial cells. Cox regression analysis showed that uPA and uPAR were the prognostic factors affecting the survival time, and they had a certain negative correlation with prognosis. Conclusion uPA and uPAR can be used as objective indicators to predict the prognosis of patients with medulloblastoma.